Cephalon Signs Option Agreement for ImmuPharma’s First-in-class Lupus Drug
By Helen Scrutton
Pharma Deals Review: Vol 2008 Issue 102 (Table of Contents)
Published: 25 Nov-2008
DOI: 10.3833/pdr.v2008.i102.105 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Cephalon has paid US$15 M upfront to obtain an option for an exclusive, worldwide licence to ImmuPharma’s Phase IIb lupus product, Lupuzor™...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS